← GMAB: big moves and long-term fundamentals中文

Genmab: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 12, 2026 · Reflects: 20-F and annual report for 2025 and the interim report for the first nine months of 2026 (6-K)

This page is information, not investment advice.

1. In one paragraph

Last updated Nov 12, 2026. Reflects the 20-F and annual report for 2025 and the interim report for the first nine months of 2026 (6-K).

Genmab invents antibody medicines. Most of its income is royalties on drugs it licensed to larger companies, above all Johnson & Johnson’s multiple myeloma drug Darzalex. In 2025 revenue was $3.72B (+19%) (annual report 2025, note 2.1), and in the first nine months of 2026 it was $3.24B (+22%) (9M 2026 report). It runs as one business segment; revenue comes in three types:

  • Royalties on Darzalex alone were $2.06B in the first nine months of 2026, 64% of revenue (our calculation)1. Genmab expects them to “begin to decline materially in 2029”, when its US patent rights expire, assuming constant underlying sales (20-F 2025).
  • It also sells two medicines of its own with partners: EPKINLY (epcoritamab, for lymphoma, with AbbVie) and Tivdak (for cervical cancer, with Pfizer).
Revenue (disclosed; shares are our calculation)2 2025 Share First nine months of 2026 Share
Royalties $3,102M 83% $2,699M 83%
Net product sales (EPKINLY in the US and Japan, Tivdak in Japan and Europe) $398M 11% $410M 13%
Milestones, reimbursements, collaboration and license revenue $220M 6% $129M 4%

2. Story so far

Last updated Nov 12, 2026. Reflects filings and company announcements through Nov 10, 2026.

In short: For most of its history Genmab has lived on royalties from drugs it discovered and licensed out, chiefly Darzalex. It is turning itself into a company that sells its own medicines: EPKINLY from 2023, then two acquisitions that brought in late-stage drugs, ProfoundBio (Rina-S) in 2024 and Merus (petosemtamab) for about $8.0B in December 2025, paid for with its first-ever borrowings of $5.5B and cash. In October 2026 three late-stage (Phase 3) trials reported positive headline results, including petosemtamab’s, and in November it kept its 2026 guidance, aiming for regulatory filings and possible launches in 2027.

Date Milestone Source
Jul 22–23, 2019 US listing of ADSs: 3.28M new shares for $582M gross, the last time Genmab sold shares for cash Annual report 2020, note 4.7
Sep 2021 US approval of Tivdak, developed with Seagen (now Pfizer) 20-F 2025
Apr 2022 An arbitration panel rules for J&J: Genmab must share J&J’s royalty payments to Halozyme for the under-the-skin version of Darzalex, which lowers Genmab’s royalty Annual report 2022, legal matters
May 2023 ★ US approval of EPKINLY, the first medicine Genmab sells itself (in the US and Japan, sharing profits 50:50 with AbbVie) 20-F 2025
May 2024 Buys ProfoundBio for $1.72B plus $199M to its award holders, adding Rina-S Annual report 2024
2024–25 Buys back 4.2M shares, 6.4% of the share capital, for $990M (our calculation)3 Annual report 2025, note 4.7
Sep 29, 2025 ★ Agrees to buy Merus for $97.00 a share in cash, about $8.0B. Genmab says a first petosemtamab launch could come in 2027 6-K
Dec 12, 2025 ★ Merus purchase completes. Genmab borrows $5.5B (term loans and notes) and uses cash on hand; on Dec 29 it drops acasunlimab, another late-stage drug 6-K, H1 2026 report, 6-K
Jan 16, 2026 EPKINLY alone beats chemotherapy on progression-free survival (time before the cancer worsens or the patient dies) in a Phase 3 lymphoma trial (EPCORE DLBCL-1), but not on overall survival, Genmab reports 6-K
Aug 6, 2026 First-half revenue +25%; 2026 revenue guidance raised H1 2026 report
Oct 5, 2026 EPKINLY plus standard chemotherapy cuts the risk of progression or death by 51% in newly diagnosed lymphoma (EPCORE DLBCL-2, headline results) 6-K
Oct 23, 2026 Rina-S beats chemotherapy on progression-free and overall survival in platinum-resistant ovarian cancer (RAINFOL-02). Start of our coverage: our article on Corcept’s fall the same day 6-K
Oct 28, 2026 ★ Genmab reports that petosemtamab plus Keytruda cut the risk of death by 50% versus Keytruda alone in previously untreated recurrent or metastatic head and neck squamous cell cancer whose tumours express PD-L1, a protein measured to select patients, at the first interim analysis (LiGeR-HN1). See our article on the stock’s rise 6-K
Nov 5, 2026 Nine-month revenue +22%; 2026 guidance kept. The CEO says the readouts support “multiple regulatory submissions and potential launches in 2027” 9M 2026 report

3. Latest quarter: did the story change?

Last updated Nov 12, 2026. Reflects Q3 2026 (quarter to Sep 30, in the nine-month report released Nov 5).

Bottom line: According to the Nov 5 report, Q3 revenue rose 16% on higher Darzalex and Kesimpta royalties and EPKINLY sales, slower than in Q2 because of lower milestone payments, and Genmab kept its 2026 guidance. Operating cash flow recovered to $520M after a weak first half, and Genmab repaid more of its Merus debt than its loan schedule required (our calculation).

Driver Last quarter → this quarter Management: before → now Signal
Revenue $1,155M (+25%) → $1,187M (+16%); milestones $5M, against $53M a year earlier 2026 guide: $4,325–4,525M (Aug 6) → kept (Nov 5); nine-month revenue $3,238M Unchanged
Darzalex royalties $744M → $751M (+14% on Q3 2025); J&J’s Darzalex sales $4,207M → $4,239M Darzalex 2026 sales assumed in the guide: $16.50–16.90B (Aug 6) → kept (Nov 5); nine-month sales $12,410M Unchanged
EPKINLY Global sales $175M → $179M (+47%); approvals with rituximab and lenalidomide (R²) in follicular lymphoma in Europe (July) and Japan (September) 2026 guide for net product sales and collaboration revenue: $595–640M (Aug 6) → kept (Nov 5) Unchanged
Costs and cash Operating cash flow $51M → $520M; Q3 adjusted operating expenses $647M (our calculation)4 2026 guide: adjusted operating expenses $2,810–2,950M and adjusted operating profit $1,065–1,385M (Aug 6) → kept (Nov 5) Better
Merus debt Borrowings $5,135M → $4,992M; principal repaid in Q3 $163M, including $150M on the Term B loan against a scheduled $50M (our calculation)5 Term B interest margin 2.00% since June; in compliance with loan covenants at Sep 30 Better

Sources: H1 2026 report, 9M 2026 report; J&J’s Darzalex sales per Genmab’s 6-K. “Adjusted” excludes acquisition and integration charges and amortization of acquired intangible assets (company definition). Growth rates are year on year. The report doesn’t explain the extra Term B repayment.

After the quarter, three Phase 3 trials reported positive headline results (section 2). In August and September Genmab started two Phase 3 trials of petosemtamab in colorectal cancer (LiGeR-CRC1 and -CRC2).

Unresolved questions: what the full results of the October trials show, and when Genmab files for approval; whether a petosemtamab launch comes in 2027 as planned; whether the faster debt repayment continues; AbbVie’s trade-secret lawsuit over Rina-S, which AbbVie has resumed in a US district court after withdrawing its trade-commission complaint.

4. Buybacks vs real dilution (5 years)

Last updated Nov 12, 2026. Reflects the treasury-share notes in the annual reports for 2022, 2024 and 2025, the 9M 2026 report and the Nov 10 warrant announcement.

Dilution in one line: From Dec 31, 2020 to Sep 30, 2026 the number of ordinary shares outstanding (excluding shares Genmab holds itself) fell 6.0%, about 1.1% a year compounded (our calculation)6. If you owned 1% of Genmab at the end of 2020, you’d own about 1.06% on Sep 30, 2026 without buying more (our calculation)7. Buybacks offset all the new shares, about 3.8 times over (our calculation)8. New shares came only from employee warrants (rights to buy new shares at a set price) and restricted stock units (awards settled in shares once vesting conditions are met). Our scale: Net reduction (the share count fell).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2020 to Sep 30, 2026FY2021–FY2025 −5.8%, 9M 2026 −0.2%. Total −6.0% since Dec 31, 2020.−6%−4%−2%0%FY2021–FY2025: −5.8% in the period; −5.8% since Dec 31, 2020−5.8%FY2021–FY20259M 2026 (part year): −0.2% in the period; −6.0% since Dec 31, 2020−0.2%9M 2026−6.0% since Dec 31, 2020

Change in the period Total since Dec 31, 2020 Part year

Shares outstanding at period end (all classes): 65.4M on Dec 31, 2020, 61.5M on Sep 30, 2026, −6.0% (our calculation). A bar below zero means the count fell (net buybacks).

Ordinary shares outstanding excluding treasury shares (Genmab's own "shares outstanding" includes them), from the annual reports and the H1 2026 report. One ADS represents one-tenth of an ordinary share.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
9M 2026 (Sep 30, 2026)61.5M−0.2%———
FY2021–FY2025 (Dec 31, 2025)61.6M−5.8%———
Dec 31, 202065.4M————

Shares outstanding from the balance sheets in the company's 20-F and 6-K filings; buybacks (cash spent) and stock-based pay from its 20-Fs, via SEC EDGAR.

How we calculated this
Share bridge, Dec 31, 2020 → Sep 30, 2026 (our calculation from disclosed share capital and treasury shares; ordinary shares, millions) Shares
Start: 65.546 issued − 0.132 held in treasury 65.414
+ New shares from employee warrant exercises (2021: 0.173, 2022: 0.243, 2023: 0.113, 2024: 0.113, 2025: 0.128, 9M 2026: 0.067) +0.837
+ Treasury shares handed to employees for restricted stock units +0.588
− Shares bought back (2021: 0.200, 2022: 0.370, 2023: 0.220, 2024: 2.012, 2025: 2.200, 9M 2026: 0.342) −5.344
End: 62.406 issued − 0.911 held in treasury 61.495 (−6.0%)
Shares issued for acquisitions, convertibles or offerings None in the period
  • Basis: Genmab’s own “shares outstanding” figure counts every issued share, including treasury shares. We subtract treasury shares, which carry no vote or dividend rights while Genmab holds them.
  • Genmab cancelled 2,076,853 treasury shares in 2025 and 1,900,000 in April 2026 (6-K). This lowers the issued count but not the outstanding count, which fell when the shares were bought.
  • The 2026 restricted-stock-unit figure (0.150M) is derived from the treasury balances (our calculation)9; earlier years are disclosed.
  • After the period: on Nov 10, 2026, employees exercised warrants for 164,828 new shares, about 0.26% of the share capital, raising about DKK 370M (6-K).
  • Genmab has not split its shares. There is one share class.

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2021 0.200M DKK 2,235 (our calculation) DKK 447M — — — Annual report 2022, note 4.7
2022 0.370M DKK 2,454 (our calculation) DKK 908M — — — Annual report 2022, note 4.7
2023 0.220M DKK 2,564 (our calculation) DKK 564M — — — Annual report 2024, note 4.7
2024 2.012M DKK 1,928 (our calculation) DKK 3,879M — — — Annual report 2024, note 4.7
2025 2.200M DKK 1,302 (our calculation from the company’s monthly averages)10 about DKK 2,864M (our calculation) — — — 20-F 2025, Item 16E
2026 YTD (to Sep 30; none in Q3) 0.342M DKK 1,798 (our calculation) DKK 615M — — — 6-K, Mar 16, 2026: 342,130 shares for DKK 615,105,001

Genmab bought back shares in every year and sold none for cash, so the prices it paid are the only prices to compare.

Notes on the prices table
  • Prices are DKK per ordinary share (10 ADSs). Average price paid is our calculation11.
  • Spending for 2021–24 includes directly attributable costs, as reported. For 2025 and 2026 it is the value of the trades; the financial statements show $430M (2025) and $96M (2026 to Sep 30) including costs (annual report 2025, H1 2026 report).
  • Purpose: the 2024 and 2025 programmes were partly to reduce capital; the others covered shares owed under the restricted stock unit programme.
  • Not counted as sales for cash: employee warrant exercises (exercise prices paid in cash, $23M in 2025).
  • Shareholders have authorised buybacks of up to 10% of the share capital until Mar 11, 2030; 5,329,268 shares were available at Sep 30, 2026 (9M 2026 report).
  • For reference, the share closed at DKK 1,795.00 in Copenhagen on Jun 30, 2026 (H1 2026 report).
Diluted shares and stock pay (disclosed; % is our calculation)12 2021 2022 2023 2024 2025 9M 2026
Weighted diluted shares (M) 66.05 66.01 65.90 64.66 62.69 Not disclosed
Stock pay as % of revenue 3.7% 3.0% 3.6% 3.4% 3.4% 3.8%

Stock pay was $85M in 2023, $105M in 2024, $128M in 2025 and $124M in the first nine months of 2026 (annual report 2025, 9M 2026 report). Restricted stock units and warrants granted in H1 2026 cover 1.15M shares, about 1.9% of shares outstanding (our calculation)13.

Insider transactions: in the 12 months to Nov 11, 2026, Genmab’s managers and board members sold 34,991 shares in the market, about DKK 124.1M, and bought none (our calculation)14. Most of it came on Nov 10, after the nine-month results, led by CEO Jan van de Winkel’s sale of 22,000 shares at DKK 3,633.75.

  • Net selling: about DKK 124.1M; other notices were shares received from vesting stock awards or warrant exercises, not market purchases.
  • Largest sellers by role: CEO Jan van de Winkel (22,000 shares, Nov 10, 2026), Chief People Officer Christopher Cozic (3,854), CFO Anthony Pagano (3,200 across Feb 19 and Nov 10), board member Pernille Erenbjerg (2,500) and Chief Development Officer Judith Klimovsky (1,265; her US Form 144 notice of the proposed sale was filed the same day).
  • Trading plans: not disclosed. As a foreign private issuer, Genmab’s insiders don’t file Forms 4; trades are published under EU market-abuse rules, and the notices don’t say whether any sale used a prearranged (Rule 10b5-1-type) plan.
Insider transactions in detail
  • Sources: the managers’ transaction notices furnished on 6-K on Nov 19, 2025, Dec 1, 2025, Feb 20, 2026, Apr 1, 2026 and May 29, 2026, and Genmab’s announcements of Nov 10, 2026 and Nov 11, 2026 (Form 144 for Klimovsky).
  • Sales: Schultz 175 shares at DKK 1,960.35 (Nov 19, 2025), Pagano 1,100 at DKK 1,810.10 (Feb 19, 2026), Kavanagh 526 at DKK 1,734.75 (May 29, 2026). On Nov 10, 2026: van de Winkel 22,000 at DKK 3,633.75, Cozic 3,854 at DKK 3,667.20, Erenbjerg 2,500 at DKK 3,656.50, Pagano 2,100 at DKK 3,670.29, Klimovsky 1,265 at DKK 3,634.01, Zachariasse 200 at DKK 3,682.50 and Schweizer 200 at DKK 3,661.79. On Nov 11: Chief Commercial Officer Bradley Bailey 1,071 at DKK 3,602.98. Two other Nov 10 notices were warrant exercises, not sales.
  • Vesting: eight board members received 189–378 shares each on Dec 1, 2025; six executives, including CEO Jan van de Winkel (8,525 shares), received shares on Apr 1, 2026.

5. Profit vs cash (latest FY and TTM)

Last updated Nov 12, 2026. Reflects the annual report 2025 and the 9M 2026 report. TTM = the four quarters to Sep 30, 2026 (our calculation)15.

Genmab’s profits turn into cash again after a weak first half. Under Genmab’s presentation, interest on the Merus debt is paid out of operating cash flow, and in H1 2026 it also paid large bills accrued at the end of 2025. Free cash flow was $1.13B in 2025, $843M over the last 12 months and $509M in Q3 alone (our calculation)16.

$M 2025 (disclosed unless marked otherwise) TTM (our calculation)
Net profit 963 729
Adjusted operating profit (company measure: operating profit excluding acquisition and integration charges and amortization of acquired intangible assets) 1,263 1,355
Operating cash flow (after interest and taxes paid) 1,186 875
Capital spending (investment in tangible and intangible assets) 55 32
Free cash flow (our calculation)17 1,131 843

Helps future profit or cash:

  • Receivables rose $166M in 2025 and $113M in the first nine months of 2026: royalties are booked when partners sell the drugs and paid later, so this cash arrives when J&J and Novartis pay.
  • The June 2026 repricing of the $1.9B Term B loan cut its interest margin by one percentage point, about $19M a year less interest (our calculation)18.

Hurts future profit or cash:

  • Interest on the Merus debt: the first nine months of 2026 included $256M of interest expense on borrowings ($82M in Q3) and $68M of amortized fees; $229M of interest was paid in cash. Interest remains a cash cost while the debt is outstanding.
  • Amortization of the Merus technology platform and other acquired intangibles ($35M in the first nine months of 2026): it lowers profit each year but uses no cash.
  • Stock pay ($128M in 2025, $124M in the first nine months of 2026): no cash cost, but it creates new shares, which the buybacks then cost cash to offset (section 4).

One-off / no lasting effect:

  • Other payables added $400M to 2025 operating cash flow and took $185M from it in the first nine months of 2026 ($269M in H1): costs accrued at year-end, chiefly for ending the acasunlimab and other programmes, bonuses, and withholding tax on Merus option payments, were paid in 2026.
  • Acquisition and integration charges ($185M in 2025, $87M in the first nine months of 2026) for the Merus deal; the company expects $90M for 2026.
  • An estimated annual effective tax rate of 3.4% in the nine-month report, against 18.9% a year earlier, because the Merus integration allows Genmab to recognise previously unrecognised tax benefits; the company says the rate is not indicative of future years. Taxes paid fell to $97M in the first nine months of 2026 from $317M a year earlier; the nine-month tax charge was $25M on pre-tax profit of $723M.
  • A $23M gain from the Term B repricing in Q2 2026: in profit, not in cash.
The raw reconciling items

From the cash-flow statements (annual report 2025, 9M 2026 report):

  • 2025: net profit before tax $1,204M; net financial items reversed −$139M; stock pay +$128M; depreciation, amortization and impairment +$103M; receivables −$166M; other payables +$400M; interest received +$135M; corporate taxes paid −$460M; operating cash flow $1,186M.
  • First nine months of 2026: net profit before tax $723M; financial income −$120M and expenses +$383M reversed; stock pay +$124M; receivables −$113M; other payables −$185M; interest received +$42M; interest paid on borrowings −$229M; corporate taxes paid −$97M; operating cash flow $574M ($3M in Q1, $51M in Q2, $520M in Q3) (9M 2026 report).
  • Under IFRS, Genmab reports interest paid in operating cash flow and lease principal ($13M in 2025, $10M in the first nine months of 2026) in financing. Our free cash flow does not deduct lease principal.
Self-funding

Funding: how long without new money? Self-funding: about $843M of free cash flow in the 12 months to Sep 30, 2026 (our calculation)17; against $1.86B of cash, Genmab owes about $5.2B on the Merus loans and notes, of which $318M is due within a year on the balance sheet; the first maturity is December 2030.

Funding details
  • As of Sep 30, 2026. Based on past cash flow; spending plans can change it. IFRS; free cash flow is operating cash flow (which includes interest and taxes paid) minus investment in tangible and intangible assets.
  • Cash and cash equivalents: $1,860M, all bank deposits. There are no marketable securities; Genmab sold them all to help pay for Merus (9M 2026 report).
  • Borrowings: $4,992M carrying value, $318M of it current. Principal outstanding is about $5,212M (our calculation)19.
  • At-the-market share-sale programme: none. Genmab pays no dividend, and its loan and note terms restrict dividends (20-F 2025, Item 8).

Extends the runway:

  • A $500M five-year senior secured revolving credit facility, undrawn at Dec 31, 2025, with nothing drawn in the Sep 30, 2026 borrowings table (annual report 2025, note 4.8; H1 2026 report, note 7).

Shortens the runway:

  • Loan repayments: $318M of borrowings is shown as current at Sep 30, 2026, from the quarterly instalments in the credit agreement (credit agreement, section 2.10). Genmab repaid $288M of principal in the first nine months, including $150M on the Term B loan in Q3, more than the scheduled instalment (our calculation)5. The original instalment schedule totals $675M of principal in the 24 months to Sep 30, 2028, before adjustments for prepayments (our calculation)20; the report doesn’t explain how the extra Q3 repayment affects later instalments. At Dec 31, 2025, principal plus interest due was $595M within one year and $1,344M in years one to three.
  • Maturities: Term A loan ($1.0B originally, 5.48% floating at Dec 31, 2025) in December 2030; Term B loan ($2.0B originally) and $1.5B of 6.25% secured notes in December 2032; $1.0B of 7.25% unsecured notes in December 2033 (annual report 2025, note 4.8).
  • Covenants, tested quarterly: secured net debt no more than 4.5 times adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, as defined in the credit agreement) through Mar 31, 2027, then 3.75 times; adjusted EBITDA at least 2.0 times cash interest, rising to 2.5 from mid-2027 and 3.0 from end-2027. Genmab was in compliance at Sep 30, 2026.

Conditional:

  • From fiscal 2026, if the year’s excess cash flow (as defined in the credit agreement) exceeds $150M, 50% of the excess must go to prepaying the loans; 25% if leverage is at or below 2.15 times, and none at or below 1.65 times.
  • Milestone payments to other companies under licence agreements, about $2.7B at Dec 31, 2025, fall due only if development, regulatory or sales milestones are reached (annual report 2025, note 5.3).

6. Customer and contract exposure

Last updated Nov 12, 2026. Reflects the 20-F 2025, the annual report 2025 and the 9M 2026 report.

Genmab depends on one partner: J&J accounted for 69% of 2025 revenue (67% in the first nine months of 2026), mostly Darzalex royalties, which have a known end date (our calculation)21. Novartis, through Kesimpta royalties, was the only other partner above 10% (13% in the first nine months of 2026).

Genmab revenue by partner, 2025
J&J (Darzalex and three other drugs): 69% of revenueJ&J (Darzalex and three other…69%Novartis (Kesimpta): 12% of revenueNovartis (Kesimpta)12%Own product sales (EPKINLY, Tivdak): 11% of revenueOwn product sales (EPKINLY, T…11%Roche (Tepezza): 3% of revenueRoche (Tepezza)3%Pfizer (Tivdak US profit share): 2% of revenuePfizer (Tivdak US profit shar…2%AbbVie: 2% of revenueAbbVie2%BioNTech and others: 2% of revenueBioNTech and others2%
Show the data
Label Value Unit
J&J (Darzalex and three other drugs) 69 % of revenue
Novartis (Kesimpta) 12 % of revenue
Own product sales (EPKINLY, Tivdak) 11 % of revenue
Roche (Tepezza) 3 % of revenue
Pfizer (Tivdak US profit share) 2 % of revenue
AbbVie 2 % of revenue
BioNTech and others 2 % of revenue

Chart source22.

Customer and contract details
  • J&J’s royalties end country by country at the later of 13 years after the first sale or the expiry of the last relevant Genmab patent. Darzalex was first sold in the US in 2015, Europe in 2016 and Japan in 2017. Genmab’s patents expire in the US in 2029 and in Europe in 2031, and begin to expire in Japan in 2030 (20-F 2025).
  • Darzalex royalties are reduced by Genmab’s share of J&J’s payments to Halozyme for the under-the-skin version, and where Genmab has no patent. Genmab is not entitled to royalties on J&J’s own patents for that version.
  • J&J can end the Darzalex licence on 150 days’ notice. Genmab would then get the rights back in the affected territory.
  • Legal: AbbVie’s trade-secret claims over Rina-S continue in a US district court after AbbVie withdrew its trade-commission complaint, which ended in July 2026; Genmab “categorically refutes” them. Chugai’s Japanese lawsuits concerning four EPKINLY patents are pending; Genmab and AbbVie believe the patents are invalid or not infringed (9M 2026 report).
  • Royalties are paid after partners’ sales, so receivables build during the year (section 5).
  • ADS holders: Genmab pays no dividend, so there is no dividend withholding tax for now; the depositary may charge ADS fees (20-F 2025).
Key contract Signed Term Size Note
J&J daratumumab licence (Darzalex) 2012 Royalties end country by country (above) Tiered royalties of 12–20% of annual sales; $920M of milestones received, up to $95M more J&J can terminate on 150 days’ notice (20-F 2025)
Novartis ofatumumab agreement (Kesimpta) 2006, with GSK; transferred to Novartis in 2015 Royalties end only where Novartis stops selling 10% royalty; no milestones left Royalty can be cut if a significant competitor launches (20-F 2025)
AbbVie epcoritamab collaboration (EPKINLY) Jun 10, 2020 Ends when neither company develops or sells licensed products; AbbVie may terminate for convenience after notice Profits shared 50:50 in the US and Japan, where Genmab books sales; 22–26% royalties elsewhere Genmab paid AbbVie $184M as its profit share in the first nine months of 2026 (9M 2026 report)
Pfizer tisotumab vedotin collaboration (Tivdak) Sep 2010 collaboration; Oct 2011 licence; Oct 2020 joint commercialization agreement Not disclosed 50% of US gross profit to Genmab; Genmab sells outside the US and China and pays Pfizer a low-teens royalty (H1 2026 report; annual report 2025, note 5.6)
J&J DuoBody licence (Rybrevant, Tecvayli, Talvey) Jul 2012, amended Dec 2013 Royalties end by country and product at the later of 10 years after first sale or the expiry of the last relevant patent Rybrevant royalties 8–10%; Tecvayli mid-single digits (H1 2026 report)

7. Genmab’s strategy for long-term growth

Last updated Nov 12, 2026. Reflects the 20-F and annual report for 2025, the 9M 2026 report and company announcements through Nov 10, 2026.

Genmab’s main income has an end date: Darzalex royalties, about two-thirds of revenue, are expected to decline from 2029. Its answer is to sell its own medicines, built partly through two acquisitions paid for with cash and its first debt, and it says the October trial results support filings and possible launches in 2027. So far its own product sales are growing fast from a small base, while costs and interest have risen.

The pressure on the core business

  • Darzalex royalties were $2.06B, 64% of revenue, in the first nine months of 2026 (section 1). Genmab’s US patents expire in 2029, its Japanese ones from 2030 and its European ones in 2031; it expects the royalties to “begin to decline materially in 2029”, assuming constant sales (20-F 2025).
  • The royalty is already reduced by Genmab’s share of J&J’s payments to Halozyme for the under-the-skin version of Darzalex, and Genmab gets no royalty on J&J’s own patents for that version (section 6).

The strategy in management’s words

  • Own medicines: EPKINLY, sold with AbbVie since 2023, was Genmab’s first. It then bought late-stage drugs: ProfoundBio (Rina-S) in 2024 for $1.72B plus $199M to award holders, and Merus (petosemtamab) in December 2025 for about $8.0B, funded with $5.5B of borrowing and cash on hand; it dropped acasunlimab, another late-stage drug, the same month (section 2).
  • On Nov 5 CEO Jan van de Winkel called the fourth quarter “data-rich”, with pivotal readouts for epcoritamab, Rina-S and petosemtamab “supporting multiple regulatory submissions and potential launches in 2027” (9M 2026 report).
  • New trials: Genmab started two more Phase 3 trials of petosemtamab, in colorectal cancer, in August and September 2026, and five Phase 3 trials of Rina-S are active or announced (9M 2026 report).

Is it working?

  • Own sales: global EPKINLY sales were $491M in the first nine months of 2026, up 47%; Genmab’s own net product sales were $410M, 13% of revenue, against Darzalex royalties of $2,057M (9M 2026 report).
  • Pipeline: three Phase 3 trials reported positive headline results in October (section 2); Genmab plans to discuss the results with regulators, and the announcements don’t disclose regulatory submissions for Rina-S or petosemtamab.
  • Cost: adjusted operating expenses rose 27% in the first nine months of 2026, which Genmab attributes mainly to the pipeline and launch preparations, and the Merus debt added $256M of interest expense (section 5).

What to watch for the strategy: the full trial results, filing dates and approvals, the first petosemtamab launch, and how fast debt falls (section 8).

8. What to watch

Last updated Nov 12, 2026. Reflects the 9M 2026 report and company announcements through Nov 10, 2026.

Date Item Source
Dec 31, 2026 Full-year guide, kept on Nov 5: revenue $4,325–4,525M, adjusted operating profit $1,065–1,385M, adjusted operating expenses $2,810–2,950M 9M 2026 report
Early 2027 (after fiscal 2026) Full-year results and 2027 guidance; first test of the excess-cash-flow loan prepayment (section 5) Annual report 2025, note 4.8
Date not set Full results of LiGeR-HN1, RAINFOL-02 and EPCORE DLBCL-2 at medical meetings, and regulatory filings; Genmab speaks of “multiple regulatory submissions” 9M 2026 report, 6-K, 6-K, 6-K
2027 Genmab expects to launch petosemtamab, subject to results and approvals. From the quarter to Jun 30, 2027, the covenant limits tighten (section 5) 6-K, annual report 2025
2029 Darzalex royalties expected to begin declining materially as US patent rights expire, assuming constant sales 20-F 2025

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 28, 2026$57.29 (Oct 28)$35.3B$38.9B9.5×10.4×36.7×31.2×+19%30%($3.6B)FY2025 (year to Dec 31, 2025)
Nov 12, 2026$51.74 (Nov 12)$31.8B$35.4B8.6×9.5×33.0×28.1×+19%30%($3.6B)FY2025 (year to Dec 31, 2025)

Our calculation from each update's filings (latest at the newest update: 20-F for the fiscal year to Dec 31, 2025); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Nov 12, 2026 price: Nasdaq and Yahoo Finance historical close (Nasdaq ADS).

Notes and calculations

  1. $2,057M Darzalex royalties ÷ $3,238M revenue, first nine months of 2026 (9M 2026 report, note 3). ↩

  2. Revenue type ÷ total. 2025: royalties $3,102M, net product sales $398M, other $220M (milestones $97M + reimbursements $53M + collaboration revenue $70M) ÷ $3,720M (annual report 2025, note 2.1). First nine months of 2026: royalties $2,699M, net product sales $410M, other $129M (reimbursements $35M + milestones $31M + collaboration $53M + license $10M) ÷ $3,238M (9M 2026 report, note 3). ↩

  3. Shares: 2,011,853 (2024) + 2,200,000 (2025) = 4,211,853, against 66,074,535 shares in issue at Dec 31, 2023 (6.4%). Spending: $560M + $430M, from the restated cash-flow statements in the annual report 2025. ↩

  4. Q3 2026: research and development $451M + selling, general and administrative $196M = $647M, which is how the nine-month adjusted figure ($1,329M + $567M = $1,896M) is built. ↩

  5. Principal repayments (9M 2026 report, note 8): nine months $288M (Term A $38M, Term B $250M) − H1 $125M (Term A $25M, Term B $100M) = Q3 $163M (Term A $13M, Term B $150M). Scheduled Term B instalment in 2026: 2.50% × $2,000M = $50M a quarter (credit agreement, section 2.10). ↩ ↩2

  6. Change = 61,494,537 ÷ 65,413,642 − 1; annual rate = (61,494,537 ÷ 65,413,642)^(1/5.75) − 1, over 5.75 years. Start: 65,545,748 shares issued − 132,106 treasury shares (annual report 2020, annual report 2022); end: 62,405,855 − 911,318 (9M 2026 report). ↩

  7. 1% × 65.414M ÷ 61.495M. ↩

  8. 5,343,983 shares bought back ÷ 1,425,000 shares added (837,000 from warrant exercises + 588,000 delivered for restricted stock units, rounded) ≈ 3.75. ↩

  9. 2,619,405 treasury shares at Dec 31, 2025 + 342,130 bought − 1,900,000 cancelled − 911,318 at Sep 30, 2026 = 150,217. ↩

  10. Item 16E monthly purchases: 316,630 shares at DKK 1,362.84, 1,152,244 at DKK 1,269.71, 611,037 at DKK 1,326.80 and 120,089 at DKK 1,324.59; sum of shares × prices = DKK 2,864.3M; ÷ 2,200,000 shares = DKK 1,301.97. ↩

  11. DKK spent ÷ shares bought back: 447 ÷ 0.200; 908 ÷ 0.370; 564 ÷ 0.220; 3,879 ÷ 2.012; 615.1 ÷ 0.342. ↩

  12. Diluted shares from the annual reports (2023–25 as restated in the annual report 2025). Stock pay ÷ revenue: 2021 DKK 310M ÷ DKK 8,417M and 2022 DKK 439M ÷ DKK 14,505M, as reported in DKK (annual report 2024); 2023 $85M ÷ $2,390M; 2024 $105M ÷ $3,121M; 2025 $128M ÷ $3,720M; first nine months of 2026 $124M ÷ $3,238M. ↩

  13. (641,408 restricted stock units + 509,290 warrants granted in H1 2026) ÷ 61.44M shares outstanding at Jun 30, 2026. ↩

  14. Sales to Oct 28, 2026: 175 × DKK 1,960.35 + 1,100 × DKK 1,810.10 + 526 × DKK 1,734.75 = DKK 3.247M (1,801 shares). Nov 10: 32,119 shares, DKK 116.99M (sum of the seven sales above). Nov 11: 1,071 × DKK 3,602.98 = DKK 3.859M. Total 34,991 shares, DKK 124.1M. ↩

  15. 2025 + first nine months of 2026 − first nine months of 2025 (9M 2026 report): net profit 963 + 698 − 932; adjusted operating profit 1,263 + 1,108 − 1,016; operating cash flow 1,186 + 574 − 885; capital spending 55 + 19 − 42. ↩

  16. 2025: $1,186M − $55M. Q3 2026: $520M operating cash flow − $11M capital spending ($7M intangible + $4M tangible). ↩

  17. Operating cash flow − capital spending, 12 months to Sep 30, 2026: $875M − $32M. ↩ ↩2

  18. 1.00 percentage point × $1,900M nominal Term B loan after the amendment (H1 2026 report, note 7). Before any effect of interest-rate swaps. ↩

  19. Nominal amounts at issue ($1,000M Term A, $2,000M Term B, $1,500M secured notes, $1,000M unsecured notes) − principal repayments to Sep 30, 2026 ($38M Term A, $250M Term B) = $5,212M. ↩

  20. Term A: 8 × $12.5M = $100M; Term B: $50M in Q4 2026 + 7 × $75M in 2027 to Q3 2028 = $575M; total $675M (credit agreement, section 2.10). Qualifying voluntary repayments can also reduce the excess-cash-flow prepayment (section 2.11(c)). ↩

  21. 2025: $2,565M J&J ÷ $3,720M; first nine months of 2026: $2,169M ÷ $3,238M. Novartis: $446M ÷ $3,720M = 12% (2025); $410M ÷ $3,238M = 13% (2026). ↩

  22. Accessed Oct 28, 2026: annual report 2025, note 2.1, revenue by collaboration partner ÷ $3,720M: J&J $2,565M, Novartis $446M, net product sales $398M, Roche $106M, Pfizer $77M, AbbVie $66M, BioNTech $40M and other $22M. Shares are rounded, so they may not sum to 100%. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Genmab: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)